-transparent.png){kind=logo}
The dose proportionality of the pharmacokinetics of fadrozole was investigated in 18 healthy postmenopausal women. Fadrozole hydrochloride was administered as 0.3-, 1.0-, and 2.0-mg oral doses continuously every 12 hr for 5 days each in a Latin square design. At steady state, the dose-normalized pharmacokinetic parameters AUC and Cmax were found to be independent of the dose. In addition, no statistically significant differences in tmax were detected. It was concluded that the pharmacokinetics of fadrozole were dose proportional in the projected therapeutic dose range. The relationship between oral clearance and the demographic factors, age, weight, and height, was assessed. Oral clearance was related to total body weight but not age or height. Prospective estimates of the population components of variance showed that intersubject variance accounted for 91.7% of the total random variance. Weight variance accounted for 36.1% of the intersubject variance.
G M Kochak, and
R L Choi, and
E A Entwistle
July 1991,
The Journal of clinical endocrinology and metabolism,
G M Kochak, and
R L Choi, and
E A Entwistle
January 1999,
Cancer,
G M Kochak, and
R L Choi, and
E A Entwistle
November 1995,
Gan to kagaku ryoho. Cancer & chemotherapy,
G M Kochak, and
R L Choi, and
E A Entwistle
July 1995,
British journal of cancer,
G M Kochak, and
R L Choi, and
E A Entwistle
January 1994,
European journal of cancer (Oxford, England : 1990),
G M Kochak, and
R L Choi, and
E A Entwistle
February 1996,
British journal of cancer,
G M Kochak, and
R L Choi, and
E A Entwistle
January 1992,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
G M Kochak, and
R L Choi, and
E A Entwistle
February 2004,
The Journal of endocrinology,
G M Kochak, and
R L Choi, and
E A Entwistle
February 1996,
Arzneimittel-Forschung,
G M Kochak, and
R L Choi, and
E A Entwistle
September 2017,
Clinical therapeutics,
